Latest Articles

Publication Date
Menopause as a Critical Turning Point in Lipedema: The Estrogen Receptor Imbalance, Intracrine Estrogen, and Adipose Tissue Dysfunction Model.

Lipedema is a chronic, estrogen-sensitive adipose tissue disorder characterized by disproportionate subcutaneous fat accumulation, fibrosis, inflammation, and resistance to fat mobilization. Despite its high prevalence, lipedema remains poorly understood and …

Published: July 23, 2025, midnight
Long-term follow-up of the effect of oral dienogest and dienogest/ethinylestradiol treatment on cell-free DNA levels in patients with deep endometriosis.

Endometriosis is currently considered a systemic inflammatory disease and different non-invasive inflammatory markers, such as cell-free DNA (cfDNA), have recently been evaluated. Hormonal treatments are frequently prescribed as first-line treatments …

Published: March 21, 2025, midnight
Smooth endoplasmic reticulum aggregates in human oocytes are related to female infertility etiology and diminished reproductive outcomes.

Smooth endoplasmic reticulum aggregates (SERa) are a type of dysmorphism in oocytes derived from controlled ovarian stimulation (COS). The effect of SERa on assisted reproductive techniques (ART) outcomes is debatable. …

Published: Feb. 28, 2025, midnight
Estradiol Promotes Endometriosis Progression Via the ERβ/QKI /circSMAD2 Axis.

The present study aimed to examine the roles of circRNA-circSMAD2 and its regulatory mechanisms in endometriosis (EMs).

Published: Feb. 20, 2025, midnight
PARP-2 acts on ILK signaling and pharmacological targeting of PARP-2 ameliorate endometriosis in a mouse model.

Endometriosis, an endocrine disorder in reproductive-aged women with an occurrence of ∼10 %, gives rise to inflammation, pelvic pain, menstrual irregularity, infertility, etc. One study demonstrated the elevated plasma level …

Published: Feb. 20, 2025, midnight
Azurocidin is Associated with Dienogest-resistance in Ovarian Endometriotic Cysts.

Endometriosis and ovarian endometrioma (OMA) cause dysmenorrhea and infertility. Current hormonal therapies for OMA treatment, may exhibit limited effectiveness. Hormonal treatments function by downregulate estrogen receptors (ERs) via progesterone receptor …

Published: Feb. 5, 2025, midnight
Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women.

Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …

Published: Feb. 1, 2025, midnight
Central Serous Chorioretinopathy in Endometriosis Treatment with Progestogen: A Metabolic Understanding.

Endometriosis afflicts 10% of women in their reproductive years and nearly half of women with infertility, and its etiology is not yet clear. Pharmacological therapy is generally based on progestins …

Published: Jan. 22, 2025, midnight
[The Levels of Progesterone Receptors are Decreased in the Invasive Areas of the Recto-Vaginal Nodules of Endometriosis].

Endometriosis is a chronic disease characterized by the growth of the endometrium outside the uterine cavity. In response to estradiol, this tissue begins to proliferate and grow, forming lesions and …

Published: Jan. 7, 2025, midnight
Nicotinamide Mononucleotide Restores NAD+ Levels to Alleviate LPS-Induced Inflammation via the TLR4/NF-κB/MAPK Signaling Pathway in Mice Granulosa Cells.

Inflammation disrupts the normal function of granulosa cells (GCs), which leads to ovarian dysfunction and fertility decline. Inflammatory conditions such as polycystic ovary syndrome (PCOS), primary ovarian insufficiency (POI), endometriosis, …

Published: Dec. 31, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!